



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁷ : A61K 39/095, C12N 1/21, C07K 14/22, A61K 39/40, C12N 15/31, A61P 31/04 // (C12N 1/21, C12R 1:36)	A2	(11) International Publication Number: WO 00/50074 (43) International Publication Date: 31 August 2000 (31.08.00)
(21) International Application Number: PCT/GB00/00624 (22) International Filing Date: 22 February 2000 (22.02.00) (30) Priority Data: 9904028.9 22 February 1999 (22.02.99) GB 9922561.7 23 September 1999 (23.09.99) GB (71) Applicants (for all designated States except US): MICROBIOLOGICAL RESEARCH AUTHORITY [GB/GB]; CAMR, Porton Down, Salisbury, Wiltshire SP4 0JG (GB). IMPERIAL COLLEGE SCHOOL OF SCIENCE, TECHNOLOGY AND MEDICINE [GB/GB]; Sherfield Building, Exhibition Road, London SW7 2AZ (GB). PUBLIC HEALTH LABORATORY SERVICE BOARD [GB/GB]; 61 Colindale Avenue, London NW9 5DF (GB). (72) Inventors; and (75) Inventors/Applicants (for US only): ROBINSON, Andrew [GB/GB]; Microbiological Research Authority, CAMR, Porton Down, Salisbury, Wiltshire SP4 0JG (GB). GORRINGE, Andrew, Richard [GB/GB]; Microbiological Research Authority, CAMR, Porton Down, Salisbury, Wiltshire SP4 0JG (GB). HUDSON, Michael, John [GB/GB]; Microbiological Research Authority, CAMR, Porton Down, Salisbury, Wilt-	shire SP4 0JG (GB). BRACEGIRDLE, Philippa [GB/GB]; Microbiological Research Authority, CAMR, Porton Down, Salisbury, Wiltshire SP4 0JG (GB). KROLL, John, Simon [GB/GB]; Imperial College School of Medicine, St. Mary's Hospital, Norfolk Place, London W2 1PG (GB). CARTWRIGHT, Keith [GB/GB]; Public Health Laboratory Service, Headquarters Office, 61 Colindale Avenue, London NW9 5DF (GB). (74) Agents: SCHLICH, George, William et al.; Mathys & Squire, 100 Gray's Inn Road, London WC1X 8AL (GB). (81) Designated States: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).	
(54) Title: NEISSERIAL VACCINE COMPOSITIONS AND METHODS		
(57) Abstract		
<p>Methods and compositions for the treatment of microbial infection, and in particular meningococcal disease, comprise a commensal <i>Neisseria</i> or an extract of a commensal <i>Neisseria</i>. Further methods and compositions comprise commensal <i>Neisseria</i> which express genes from virulent strains of <i>Neisseria</i> and/or heterologous gene products from non-neisserial sources. Such compositions are used in vaccine preparations for the treatment of microbial infection.</p>		

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece	ML	Mali	TR	Turkey
BG	Bulgaria	HU	Hungary	MN	Mongolia	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MR	Mauritania	UA	Ukraine
BR	Brazil	IL	Israel	MW	Malawi	UG	Uganda
BY	Belarus	IS	Iceland	MX	Mexico	US	United States of America
CA	Canada	IT	Italy	NE	Niger	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NL	Netherlands	VN	Viet Nam
CG	Congo	KE	Kenya	NO	Norway	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NZ	New Zealand	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	PL	Poland		
CM	Cameroon	KR	Republic of Korea	PT	Portugal		
CN	China	KZ	Kazakstan	RO	Romania		
CU	Cuba	LC	Saint Lucia	RU	Russian Federation		
CZ	Czech Republic	LI	Liechtenstein	SD	Sudan		
DE	Germany	LK	Sri Lanka	SE	Sweden		
DK	Denmark	LR	Liberia	SG	Singapore		
EE	Estonia						

NEISSERIAL VACCINE COMPOSITIONS AND METHODS

- 5 The present invention relates to vaccines and methods for preparing vaccines that stimulate an immune response. In particular, the present invention relates to vaccines that provide broad spectrum protective immunity to microbial infection.
- 10 Infection by pathogenic organisms is one of the major causes of chronic and acute disease. In particular, infection resulting from microbial sources - such as bacteria, viruses and protozoans - continue to claim millions of lives worldwide. With microbial species increasingly becoming resistant to conventional antibiotics, it would be desirable to provide alternative and
- 15 preferably prophylactic means of protecting against and fighting microbial infection.
- Meningococcal meningitis is of particular importance as a worldwide health problem and in many countries the incidence of infection is increasing.
- 20 *Neisseria meningitidis* (the meningococcus) is the organism that causes the disease and is also responsible for meningococcal septicaemia, which is associated with rapid onset and high mortality, with around 22% of cases proving fatal.
- 25 At present, vaccines directed at providing protective immunity against meningococcal disease provide only limited protection because of the many different strains of *N. meningitidis*. Vaccines based upon the serogroup antigens, the capsular polysaccharides, offer only short lived protection against infection and do not protect against many strains commonly found
- 30 in North America and Europe. A further drawback of these vaccines is that they provide low levels of protection for children under the age of 2 years, one of the most vulnerable groups that are commonly susceptible to

- 2 -

infection. Newer conjugate vaccines now in use in the UK will address some of these problems but will only be effective against the C serogroup of the meningococcus

5 Gold *et al.* (Journal of Infectious Diseases, volume 137, no. 2, February 1978, pages 112-121) have reported that carriage of *N. lactamica* may assist in the development of natural immunity to *N. meningitidis* by induction of cross-reactive antibodies. This conclusion was based on the observation of cross-reacting antibodies having complement-dependent bactericidal
10 activity produced in response to *N. lactamica* infection. However, Cann and Rogers (J. Med. Microbiol., volume 30, 1989, pages 23-30) detected antibodies to common antigens of pathogenic and commensal neisseria species, but observed also that antibody to the same antigens was present in both bactericidal and non-bactericidal sera. Thus, it was not possible to
15 identify any cross-reactive bactericidal antibodies.

Live attenuated vaccines for meningococcal disease have been suggested by Tang *et al.* (Vaccine 17, 1999, pages 114-117) in which a live, attenuated strain of *N. meningitidis* could be delivered mucosally. Tang also commented
20 on the use of commensal bacteria to protect against infection by pathogenic bacteria, concluding that the cross-reactive epitopes that induce protection against meningococcal infection have not been defined, and therefore that use of genetically modified strains of *N. meningitidis* would be preferred.

25 It is desirable to provide a further vaccine that gives protective immunity to infection from *N. meningitidis*. It further is desirable to provide a vaccine that confers protective immunity to infants as well as adults and whose protection is long term. It may also be of advantage to provide a vaccine that protects against sub-clinical infection, i.e. where symptoms of
30 meningococcal infection are not immediately apparent and the infected individual may act as a carrier of the pathogen. It would further be of advantage to protect against all or a wide range of strains of *N. meningitidis*.

- 3 -

It is still further desirable to provide a vaccine against other neisserial infection, notably gonorrhoea.

5 It is an object of the present invention to provide compositions containing immunostimulating components, and vaccines based thereon, that meet or at least ameliorate the disadvantages in the art.

10 The present invention is based on the use of a commensal *Neisseria* in a vaccine against disease. Accordingly, a commensal species of *Neisseria* such as *N. lactamica* may be used as a live vaccine or a killed whole cell vaccine, or in a vaccine containing fractions of *N. lactamica*. It has surprisingly been demonstrated that mice immunised according to the present invention with *N. lactamica* killed whole cells and outer membrane preparations are protected from lethal intraperitoneal meningococcal challenge, and that
15 vaccines composed of a detergent extract of *N. lactamica* cells or fractions of this, separated by preparative electrophoresis, also protect mice from lethal meningococcal challenge. These results have been obtained using mice and the mouse model used is regarded as predictive of corresponding immunogenic and vaccinating effects in humans.

20 Accordingly, a first aspect of the present invention provides an immunogenic composition, comprising a commensal *Neisseria* or an immunogenic component, extract or derivative thereof and a pharmaceutically acceptable carrier.

25 The composition of the invention is particularly suited to vaccination against infection of an animal. The term "infection" as used herein is intended to include the proliferation of a pathogenic organism within and/or on the tissues of a host organism. Such pathogenic organisms typically include
30 bacteria, viruses, fungi and protozoans, although growth of any microbe within and/or on the tissues of an organism are considered to fall within the term "infection".

Commensal micro-organisms are those that can colonize a host organism without signs of disease. A number of different commensal *Neisseria* are suitable for use in the invention, and these commensal *Neisseria* may be selected from the group consisting of *N. lactamica*, *N. cinerea*, *N. elongata*,
5 *N. flavescens*, *N. polysaccharea*, *N. sicca* and *N. subflava*. Different species of these commensal organisms are known to colonise the buccal or nasal areas or other mucosal surfaces and hence each species may be administered according to the known area of the body it normally colonises. Hence also, use of a composition of the invention may result in stimulation
10 of production of protective antibodies *de novo* or if the individual has already been colonised to a certain extent may result in an enhancement of naturally-existing antibodies.

The "extract" or "component" is an extract or component that is immunogenic such that antibodies raised against the extract or component
15 of a commensal *Neisseria* cross react with a pathogenic *Neisseria*, in particular *N. meningitidis*.

The term "derivative" is used to describe types and strains of commensal
20 *Neisseria* that are modified or attenuated in some way so as to differ from the wild type species; for example, a vaccine composition comprising a recombinant commensal *Neisseria* that exhibits resistance to certain types of antibiotic compounds, which might advantageously be utilised in combination with such antibiotics in the treatment of infection.

It is an advantage of the invention that vaccination against neisserial
25 diseases may thus be achieved using a non-pathogenic species of *Neisseria*, rendering the vaccination a safer procedure. Furthermore, the protection conferred surprisingly may not be restricted to a specific serotype, subtype
30 or serogroup of the meningococcus but is of general protective efficacy.

A further advantage of the invention is that the commensal *Neisseria* that are

- 5 -

the subject of the invention can not revert to virulent types. It is known in the vaccination field to use live, attenuated pathogens and this use carries the risk that the attenuated organism may revert to virulence. This risk is avoided by the present invention. Furthermore, *N. meningitidis* possesses many virulence factors the precise roles of which in pathogenesis are unknown and may possess hitherto unrecognised virulence factors. Therefore, an additional advantage of the invention is that a composition of the invention can be used with confidence in its level of safety.

The method of the invention is of application to vaccination against various infections, preferably but not only neisserial infections. In a specific embodiment of the invention, protection against meningococcal disease has been demonstrated. The invention is also of application to vaccination generally against neisserial infection, including gonorrhoeal infection, and also to infection from other pathogenic microbial organisms. The invention further provides for vaccination that is aimed at either stimulating or desensitizing the immune system.

The composition can specifically comprise killed commensal *Neisseria*, which may for example be obtained by heat or by suspending commensal *Neisseria* in a mixture of bactericidal agents such as thiomersal and formaldehyde.

The composition may also comprise live commensal *Neisseria*. As mentioned, it is optional but not usually required to use attenuated commensal *Neisseria* as these organisms are avirulent.

In an embodiment of the invention, an immunogenic component or extract of a commensal *Neisseria* is selected from an outer membrane vesicle preparation, an outer membrane preparation, lipooligosaccharide and a protein fraction.

The outer membrane preparation and protein fraction of *N. lactamica*, for

example, can be obtained from *N.lactamica* cultured in the presence or absence of iron. The protein fraction of *N.lactamica* is conveniently obtained by suspending *N.lactamica* cells or membranes in the presence of detergent and incubating the suspension so as to extract proteins from the

5 *N.lactamica*.

Alternatively, a number of other techniques are known for extraction of outer membrane components - such as protein fractions, lipooligosaccharides and lipopolysaccharides - from cell preparations and are suitable to obtain the

10 commensal *Neisseria* immunogenic components or extracts of the invention. Examples of conventional techniques for this purpose include the use of variation in salt concentration, chaotropic agents, variation in pH (high or low), enzymic digestion and mechanical disruption.

15 A number of different fractions are suitable for use in vaccinating against meningococcal disease. Particularly suitable fractions are those of molecular weight less than 50kDa, of molecular weight more than 40kDa and less than 70kDa, and of molecular weight more than 60kDa.

20 In more specific embodiments of the invention there is provided a composition for eliciting an immune response and suitable for use in vaccinating an individual against neisserial infection, more specifically meningococcal disease, comprising an antigenic component or antigenic components having the properties:-

- 25 (a) molecular weight 50kDa or lower;
(b) obtainable from *N. lactamica*; and
(c) antibodies to the component(s) obtained from *N. lactamica* cross-react with *N. meningitidis*.

30 In use of a composition containing such a component, extracted using detergent, all mice treated with this component survived a challenged dose of 2×10^7 CFU *N. meningitidis* and three out of five mice survived a higher

- 7 -

challenge dose of 6×10^8 CFU.

Another specific embodiment of the invention lies in a composition for eliciting an immune response and suitable for use in vaccinating an individual against neisserial infection, more specifically meningococcal disease, comprising an antigenic component or antigenic components having the properties:-

(a) molecular weight at least 40kDa and up to 70kDa;

(b) obtainable from *N. lactamica*; and

(c) antibodies to the component(s) obtained from *N. lactamica* cross-react with *N. meningitidis*.

In use of such a component of the invention, obtained using a detergent extract of *N. lactamica*, four out of five mice treated with the component survived a challenge dose of 2×10^7 CFU *N. meningitidis* and mice receiving a higher challenge dose of 6×10^8 CFU survived longer than a control group.

A still further embodiment of the invention lies in a composition for eliciting an immune response and suitable for use in vaccinating an individual against neisserial infection, more specifically meningococcal disease, comprising an antigenic component or antigenic components having the properties:-

(a) molecular weight at least 60kDa;

(b) obtainable from *N. lactamica*; and

(c) antibodies to the component(s) obtained from *N. lactamica* cross-react with *N. meningitidis*.

In use of such a component, obtained using a detergent extract, one out of five mice survived a challenge dose of 2×10^7 CFU *N. meningitidis* and, whilst all mice succumbed to a higher challenged dose of 6×10^8 CFU, their survival time was longer than a control group which did not receive the component.

- 8 -

In an example of the invention in use, described in more detail below, proteins in the size ranges of 25-35 kDa and 35-43 kDa, extracted from a commensal *Neisseria*, conferred a significant level of immune protection when administered to mice as a vaccine composition.

5

By way of example of a method of extracting an antigenic component of the invention, an extraction method comprises:-

10

(i) suspending *N.lactamica*, cells in an aqueous solution of detergent;

(ii) incubating the suspension so as to extract the antigenic component from the *N.lactamica*;

15

(iii) centrifuging the suspension to separate the suspension into a supernatant and a pellet; and

(iv) fractionating the antigenic component from the supernatant.

20

This specific method can be modified according to the extraction protocol selected by the user, for example by using high salt concentration in the initial step (i). In further embodiments of the invention the antigenic component is obtained using recombinant technology by expression of a *N. lactamica* sequence in a suitable host such as *E. coli*.

25

In a second aspect of the invention there is provided a composition for vaccination against neisserial infection comprising a commensal *Neisseria* or an immunogenic component, extract or derivative thereof and a pharmaceutically acceptable carrier, wherein the commensal *Neisseria* comprises and expresses a gene from a pathogenic *Neisseria*.

30

This aspect of the invention offers the benefit of use of a commensal

- 9 -

organism to deliver and/or present to the recipient an antigen from a pathogenic *Neisseria*. The gene optionally encodes a surface antigen or a protein that is secreted, and may code for an antigen from, for example, *N. meningitidis* or *N. gonorrhoeae*. The commensal *Neisseria* can be live or killed.

In an embodiment of the second aspect of the invention there is provided a composition for vaccination against meningococcal disease comprising a commensal *Neisseria* and a pharmaceutically acceptable carrier, wherein the commensal *Neisseria* comprises and expresses a *N. meningitidis* gene.

The *N. meningitidis* gene may encode for example a transferrin binding protein, a superoxide dismutase (SOD) for example a Cu,Zn SOD, neisserial surface protein A ("NspA"), a porin or another outer membrane protein. Gene sequences for the majority of these antigens are known in the literature. Kroll *et al.* in Microbiology 141 (Pt 9), 2271-2279 (1995) describe the sequence of Cu,Zn-SOD. Martin *et al.* in J Exp Med, 1997, April 7th, 185(7), pp1173-1183 describe the sequence of NspA from *N. meningitidis*.

The invention also provides a pharmaceutical composition comprising a composition according to the first or second aspect of the invention plus a pharmaceutically acceptable carrier.

In a third aspect, the invention provides a method of vaccination against neisserial infection, comprising administering an effective amount of a composition according to the first and second aspects of the invention.

In use of an embodiment of the invention described in an example below, there is provided a method of vaccination against meningococcal disease, comprising administering an effective amount of a composition according to the first and second aspects of the invention.

In a fourth aspect of the invention there is provided a strain of a commensal *Neisseria*, such as *N. lactamica*, genetically modified so as to express a gene from a pathogenic *Neisseria*. The *N. meningitidis* gene may for example code for a protein selected from a transferrin binding protein, a SOD for example a Cu,Zn-SOD, NspA, a porin or another outer membrane protein.

The invention further provides, in a fifth aspect a method of extracting a protein for incorporation in a composition suitable for vaccinating against meningococcal disease, comprising:-

- (i) suspending commensal *Neisseria*, for example *N. lactamica*, cells in the presence of detergent; and
- (ii) incubating the suspension so as to extract a protein fraction from the cells.

The protein fraction can suitably be of molecular weight 50kDa or lower, at least 40kDa and up to 90kDa or at least 80kDa.

The composition may be combined with a pharmaceutically acceptable carrier - for example the adjuvant alum although any carrier suitable for oral, intravenous, subcutaneous, intraperitoneal intramuscular, intradermal or any other route of administration is suitable - to produce a pharmaceutical composition for treatment of meningococcal disease. Commensal *Neisseria* that are buccal colonizers can be administered in a mouthwash and nasal colonizers in a nasal spray.

Transferrin binding proteins are known to be located on the outer membranes of a number of Gram negative bacteria such as *N. meningitidis*. Formulations of the composition of the present invention with conventional carriers or adjuvants and optionally further supplemented by one or more antigens from *Neisseria* species, optionally recombinantly produced, for

- 11 -

example, Cu-Zn SOD, the 22kD NspA, porins, gonorrhoeal antigens or transferrin binding proteins provide a composition for treatment of infection by these bacteria.

5 In the present invention, the term "transferrin binding protein" or "Tbp" refers to a protein which either alone binds to transferrin or can be part of a complex of proteins that binds transferrin. The term also embraces fragments, variants and derivatives of such a protein provided that antibodies raised against the fragment, variant or derivative bind the protein.

10 Thus, TbpA and TbpB either dissociated or associated into a complex are considered to be Tbp. Moreover, mutants, fusion proteins or fragments of either TbpA or B or other derivatives of the TbpA + B complex with a common antigenic identity are also considered to be represented by the term Tbp in the present invention.

15

A live vaccine according to the present invention may be administered parenterally or to the mucosa for example via intranasal or oral inoculation. A killed bacteria or subunit vaccine may also be given by this route, or formulated for oral delivery. A subunit vaccine is conveniently administered

20 via the parenteral route. Different commensal *Neisseria* and different strains of *N. lactamica* from those tested in specific embodiments of the invention exist, and the invention is of application also to those other strains.

25

A sixth aspect of the invention provides a composition comprising an antibody, wherein the antibody binds to a commensal *Neisseria* of the first or second aspects of the invention or an immunogenic component or extract thereof. In use, the antibody can be formulated into a pharmaceutical composition for treatment of neisserial infection, such as meningococcal disease or infection caused by other *Neisseria*.

30

An antibody according to this aspect of the invention can be obtained following standard techniques, for example by inoculating an animal with the

- 12 -

commensal *Neisseria* or an immunogenic component or extract thereof and thereafter isolating antibodies that bind to the commensal *Neisseria* or the immunogenic component or extract thereof.

5 A further aspect of the invention provides for a composition comprising a commensal *Neisseria*, or an immunogenic component, extract or derivative thereof, wherein said *Neisseria* comprises a heterologous gene product.

10 Heterologous gene products of the invention typically include peptides, proteins and antisense sequences that are coded for by a gene sequence that is not native to the commensal *Neisseria*. Typical heterologous gene products of the invention include, for example, bacterial proteins, viral proteins or surface peptides, antigens and antibodies and fragments thereof. The heterologous gene product of the invention may also be any antigen
15 found in a pathogenic organism.

In an embodiment of the invention, the composition comprises a commensal *Neisseria* into which has been transformed an expression vector containing a gene sequence encoding a heterologous gene product. Specific proteins
20 suitable for use in the invention typically include:-

25 Viral proteins - such as hepatitis B virus surface antigen; rabies virus glycoprotein G; herpes simplex virus glycoprotein D; Epstein-Barr virus glycoprotein; influenza virus glycoprotein; vesicular stomatitis virus nucleoprotein; human respiratory syncytial virus glycoprotein G; human immunodeficiency virus (HIV) envelope; rotavirus subunits; measles virus subunits; and vaccinia virus subunits.

30 Bacterial proteins - such as *Bordetella pertussis* fimbrial subunits; *Bordetella pertussis* surface proteins; *Bacillus anthracis* subunits; *Escherichia coli* subunits; and *Yersinia pestis* subunits.

- 13 -

Protozoan proteins - such as *Plasmodium falciparum* proteins; trypanosome proteins; and *Cryptosporidium* proteins.

5 In a further embodiment the composition of the invention suitably provides for a commensal *Neisseria* that expresses a heterologous gene product which is immunostimulatory for treatment of non-infectious disease, for example allergy and cancer. In an example of the invention in use a commensal *Neisseria* that expresses peanut antigens is used to desensitize a patient with acute peanut allergy.

10 In a further example of the invention in use, described in more detail below, the expression vector pJSK422 is used to express green fluorescent protein, under the control of the groES/EL promoter, in the commensal *N. cinerea*.

15 The invention further provides for a commensal *Neisseria* that is transformed with an expression vector that comprises a signal sequence that directs the heterologous gene product to the outer membrane of the neisserial cell. Other signal sequences are also suitable for use in the invention, such as secretion signals or cellular subcompartment localisation signals e.g. periplasmic localisation signals.

20 Further aspects of the invention provide methods for preparing compositions. Such methods are suitable for preparing vaccine compositions that elicit protective immunity to microbial infection when administered to an animal.

25 An example of the invention in use, described in more detail below, provides for a method of preparing a composition comprising the steps of:

30 a) inserting a gene coding for a heterologous gene product into an expression vector;

b) transforming said expression vector into a commensal

- 14 -

Neisseria so that said heterologous gene product is expressed in said *Neisseria*; and

- 5 c) combining the *Neisseria* of (b) with a pharmaceutically acceptable carrier.

A further example of the invention, provides for a method of preparing a composition comprising the steps of:

- 10 a) inserting a gene coding for a heterologous gene product into an expression vector;
- b) transforming said expression vector into a commensal *Neisseria* so that said heterologous gene product is expressed
- 15 in said *Neisseria*;
- c) obtaining an immunogenic component or extract from the *Neisseria* of (b); and
- 20 d) combining the immunogenic component or extract of (c) with a pharmaceutically acceptable carrier.

In yet a further example of the invention in use is provided a method of preparing a composition comprising the steps of:

- 25 a) obtaining an immunogenic component or extract from a commensal *Neisseria*; and
- b) combining the immunogenic component or extract of (a)
- 30 with a heterologous gene product and a pharmaceutically acceptable carrier.

- 15 -

Thus, the invention provides for (a) methods and compositions in which an extract is taken from a commensal *Neisseria* that expresses a heterologous gene product, and (b) methods and compositions where an extract is obtained from a commensal *Neisseria* and the heterologous gene product expressed elsewhere (in another organism) is combined with this latter extract.

Further aspects of the invention provide for use of a commensal *Neisseria* in the manufacture of a medicament for treatment of neisserial infection, and for use of a commensal *Neisseria*, or an immunogenic component, extract or derivative thereof, wherein said *Neisseria* comprises a heterologous gene product, in the manufacture of a medicament for the treatment of infection or for immunostimulation in an animal.

Specific embodiments of the invention are discussed in more detail by means of the Examples described below. The results referred to in the Examples are illustrated by the accompanying drawings, in which:

Fig. 1 shows protection of mice against intraperitoneal ("IP") infection with *N.meningitidis* strain K454 by use of *N.lactamica* whole cells and outer membrane fractions;

Fig. 2A shows protection of mice against IP infection with *N.meningitidis* strain K454 by use of detergent and high, medium and low molecular weight extracts of *N.lactamica* cells - upper panel = challenge by 2×10^7 CFU, lower panel = challenge by 6×10^8 CFU;

Fig. 2B shows the components of the high, medium and low molecular weight fractions of fig.2A;

Fig. 3 shows an immunoblot illustrating cross-reaction of antibodies in sera from meningococcal disease patients with proteins from *N.lactamica*

strain Y92-1009;

Fig. 4 shows a photograph of a gel on which subfractions of low molecular weight outer membrane protein extract have been run; and

Fig. 5 shows protection of mice against IP infection with *N.meningitidis* strain K454 when immunised with low molecular weight subfractions - upper panel=challenge by 5×10^6 CFU, lower panel=challenge by 1×10^8 CFU.

Fig. 6 shows a histogram comparing the fluorescence of *N. cinerea* NRL 32165 containing pJSK411 (promoterless GFP) to pJSK422 (pJSK411 with groEL/ES promoter).

Example 1

Preparation of vaccine containing killed whole cells

Neisseria lactamica strain Y92-1009 was grown in Mueller Hinton broth (MHB) containing $5\mu\text{gml}^{-1}$ ethylenediamine-di(o-hydroxyphenylacetic acid) (EDDHA), incubated at 37°C with shaking (140rpm) for approximately 6h.

Bacteria were then harvested by centrifugation and resuspended in phosphate buffered saline (PBS) containing 1% (v/v) formaldehyde and 0.1% (w/v) thiomersal, and left to stand overnight at $2-8^\circ\text{C}$. Killed cells were then resuspended in PBS to an OD_{650} of 1.0 (equivalent to 2×10^9 CFU ml^{-1}) and alhydrogel added to 25% (V/V), yielding a product suitable for subcutaneous administration.

This method is suitable also for *N. cinerea*, *N. elongata*, *N. flavescens*, *N. polysaccharea*, *N. sicca* and *N. subflava*.

Example 2**Preparation of vaccine containing *N. lactamica* outer membrane (OM) preparations**

5 *N. lactamica* strain Y92-1009 was grown in MHB with and without the addition of $5\mu\text{gml}^{-1}$ EDDHA overnight at 37°C with shaking. Iron limited (with EDDHA) and iron replete cells were then treated separately. Bacteria from 1.5 litres were harvested by centrifugation and resuspended in 20ml
10 200mM Lithium acetate, 5mM EDTA, pH 6.0 and incubated for 3h at 37°C with shaking. Bacteria were then passed 7 times through a 21 gauge needle and pelleted at 8000g for 10min.

15 The supernatant was recovered and membranes pelleted by centrifugation at 100,000g for 1h at 4°C . The membranes were then resuspended in 10mM HEPES, pH 7.4, containing 0.1% (v/v) 10mM PMSF, yielding OM-containing vaccinating preparations. The protein content of the OM vaccine preparations was determined using the bicinchoninic acid assay (Sigma, UK).
20 OM's were diluted in sterile deionized water to give a protein concentration of $100\mu\text{gml}^{-1}$. This was then mixed with an equal volume of Freund's adjuvant, to give a final protein concentration of $50\mu\text{gml}^{-1}$, and emulsified thoroughly. Freund's complete adjuvant was used for the primary dose, and Freund's incomplete for subsequent boosts.

Example 3**Preparation of vaccine containing lipooligosaccharide (LOS)**

30 Purification of LOS was carried out from *N. lactamica* strain Y92-1009 using the method of Gu, X-X and Tsai, C.M. (1991) Anal Biochem. **196**; 311-318. Vaccine was prepared using Freund's adjuvant as above with LOS at a final concentration of $10\mu\text{gml}^{-1}$.

Example 4**Vaccination and challenge schedule**

5 Groups of 5 mice were vaccinated with each preparation as follows:-

Prime:- Day 0
First boost:- Day 21
Second boost:- Day 28

10 Mice vaccinated with killed cells of Example 1 received 0.5ml subcutaneously, equivalent to 1×10^9 CFU. Mice vaccinated with OM of Example 2 and LOS of Example 3 received 0.2ml subcutaneously; equivalent to $10\mu\text{g}$ of protein and $2\mu\text{g}$ of LOS.

15 On day 35, mice were challenged by intraperitoneal injection with approximately 10^8 CFU *N. meningitidis* K454 made up in MHB containing transferrin at a final concentration of 20mg/ml. The mice were then examined and the number of survivors noted and the results are shown in fig.1. After 4 days all 5 mice survived in the groups vaccinated with whole
20 cells and OMPs (without iron) and 3 survived in the group vaccinated with OMPs (with iron). After 5 days all members of the control group and of the group vaccinated with LOS (marked LPS on the figure) had died.

Example 5

25

Preparation of vaccine comprising *N. lactamica* fractions

Brain heart infusion agar plates were inoculated with $50\mu\text{l}$ of *N. lactamica* strain Y92-1009 and incubated overnight at 37°C , with 5% CO_2 . This was
30 used to inoculate a 100ml MHB starter culture which was incubated with shaking at 37°C for 6 h. Starter culture (15ml) was added to each of 6x500ml volumes of MHB. These were then incubated with shaking

- 19 -

overnight at 37°C and the conditions were made iron-limited by the addition of 5 µg/ml¹ EDDHA. The cells were harvested by centrifugation and the supernatant discarded. The cells were washed with 100ml PBS and then pelleted by centrifugation. Cell pellets were resuspended in PBS + 0.3% (v/v) Elugent (Calbiochem, 2ml per g wet weight) and incubated with shaking at 37°C for 20 min. The cells were then removed by centrifugation and the pellet discarded. EDTA and N-lauroyl sarcosine were then added to the supernatant to 10mM and 0.5% (w/v) respectively.

The BioRad (Registered Trade Mark) Prep Cell, model 491 was then used to separate the proteins contained in the detergent extract. A 4cm, 7% acrylamide native resolving gel was cast with a 2 cm stacking gel. 12mg of protein in native sample buffer was electrophoresed using running buffer containing 0.1% (w/v) SDS, 0.025M Tris and 0.192M glycine at 40mA and 400V until the dye front reached the bottom of the gel. 3ml fractions of the eluted proteins were then collected. Once the fractions were collected they were pooled into groups consisting of proteins of molecular weight approximately less than 40kDa, between 40 and 67kDa and more than 67kDa. The pooled proteins were concentrated by ammonium sulphate precipitation and dialysed against PBS. These were diluted in PBS to a protein concentration of 100 µg/ml and Freund's complete adjuvant was added at a ratio of 1:1(v/v) or Freund's incomplete adjuvant for booster doses.

Example 6

Vaccination and challenge schedule

Groups of 5 mice were vaccinated with each preparation as follows:-

Prime:-	Day 0
First boost:-	Day 21
Second boost:-	Day 28

- 20 -

Mice were vaccinated with no vaccine (i.e control group), Elugent ("Registered Trade Mark") extract or high, medium or low molecular weight fraction. The mice receiving the protein fraction groups received 0.2ml subcutaneously; equivalent to 10 μ g of protein.

5

On day 35 mice were challenged by intraperitoneal injection with either approximately 2 x 10⁷ or 6 x 10⁸ CFU *N. meningitidis* K454 made up in MHB containing transferrin at a final concentration of 20mg/ml. The mice were then examined over four days and the number of survivors noted, and the results are shown in fig.2A - upper panel 2 x 10⁷ challenge and lower panel 6 x 10⁸ challenge. The components of the high, medium and low molecular weight fractions are shown in fig.2B. after being run an SDS-PAGE gel.

10

Example 7

15

Samples of human sera following meningococcal disease were investigated and these showed that antibodies were produced which react with a range of *N. lactamica* proteins. The results of the immunoblot are shown in fig.3.

Example 8

20

25

30

Due to the level of protection offered by the low molecular weight pool in Example 6 (see Fig. 2A), further separation of these proteins was carried out, according to the method of Example 5, to further characterise components responsible for protection. Proteins were pooled into three groups consisting of <25 kDa (g1), 25-35 kDa (g2) and 35-43 kDa (g3)(shown in Fig. 4). Determination of the levels of lipopolysaccharide (LPS) revealed high levels of LPS in fraction g1 [26 580 endotoxin units per ml (EUml⁻¹)], and considerably lower levels in the remaining fractions (9149 EUml⁻¹ in g2 and 9348 EUml⁻¹ in g3).

As in previous examples, groups of five mice were immunised, using a three

dose schedule with one of the three groups of proteins described above, proteins >43 kDa and detergent extract of killed whole *N. lactamica* cells and killed whole *N. lactamica*. Animals were challenged with *N. meningitidis* serogroup B, strain K454, at a dose of 5×10^6 or 1×10^8 CFU, together with unimmunised controls. The number of survivors on each day post challenge is shown in Fig. 5.

All mice, apart from the control group and one mouse in group g3, survived the lower challenge dose; however, at the higher challenge dose the g2 and g3 protein groups (25-35 kDa and 35-43 kDa respectively) offered best protection.

Example 9

Commensal *Neisseria* as a vehicle for recombinant protein expression

The gene encoding the measles virus nucleocapsid protein was cloned into the pMGC18.1 shuttle vector (Webb *et al.*, 1998, poster at the 11th International Pathogenic *Neisseria* Conference, Nice) and transformed into *E. coli* DH5alpha. Expression of the measles virus nucleocapsid protein was confirmed by western blotting probed with specific antiserum. This construct was then used to transform *N. lactamica* by conjugation. Expression of the measles virus nucleocapsid protein was placed under the control of the neisserial *frpC* promoter and expression at high levels was seen when the bacteria were grown under iron-limited growth conditions.

Example 10

Expression of GFP in the commensal *N. cinerea*

The green fluorescent protein (GFP) gene of *Aequorea victoria* was inserted

- 22 -

into the pJSK422 plasmid using standard cloning techniques. The GFP was under the control of the groES/EL promoter. As a negative control the GFP gene was also inserted into the pJSK411 plasmid which lacks the groES/EL promoter of the pJSK422 plasmid.

5

N. cinerea was transformed via conjugation (see Example 9) either with the pJSK422 or pJSK411 (negative control) GFP containing plasmids. The transformed cells were cultured under appropriate conditions. Fluorescence of the pJSK422 transformed cultures of *N. cinerea* were compared to that of the pJSK411 transformed cultures. The results of the comparison are shown in Fig. 6. The histogram shows intensity of GFP fluorescence on the X axis and the number of cells fluorescing on the Y axis. It is clear that the level of fluorescence is higher in the *N. cinerea* transformed with pJSK422 than those transformed with pJSK411, indicated by the peak shift to the right. This, demonstrates heterologous expression of the GFP gene in the commensal *N. cinerea*.

10

15

The invention thus provides immunogenic compositions and vaccines for use in protecting against disease.

CLAIMS

1. A vaccine composition comprising a commensal *Neisseria* or an immunogenic component, extract or derivative thereof.
2. A composition according to Claim 1 comprising killed *Neisseria*.
3. A composition according to Claim 2 wherein killed *N.lactamica* are obtained by suspending *N.lactamica* in a mixture of bactericidal agents such as thiomersal and formaldehyde.
4. A composition according to Claim 1 comprising live *N. lactamica*.
5. A composition according to Claim 1 wherein the immunogenic component or extract of *Neisseria* is selected from an outer membrane preparation, a lipooligosaccharide and a protein fraction.
6. A composition according to Claim 5 wherein the *Neisseria* is *N. lactamica*.
7. A composition according to Claim 5 wherein the immunogenic component or extract comprises a protein fraction of molecular weight less than 40kDa.
8. A composition according to Claim 5 wherein the immunogenic component or extract comprises a protein fraction of molecular weight more than 40kDa and less than 67kDa.
9. A composition according to Claim 5 wherein the immunogenic component or extract comprises a protein fraction of molecular weight more than 67kDa.
10. A composition according to any of Claims 7 to 9 wherein a protein

fraction of *N.lactamica* is obtained by suspending *N.lactamica* cells in the presence of detergent and incubating the suspension so as to extract proteins from the *N.lactamica*.

11. A composition for eliciting an immune response and suitable for use in vaccinating an individual against neisserial infection, comprising an antigenic component having the properties:-
 - (a) it is of molecular weight 50kDa or lower;
 - (b) it is obtainable from a commensal *Neisseria*; and
 - (c) antibodies to the component obtained from the commensal *Neisseria* cross-react with *N. meningitidis*.
12. A composition for eliciting an immune response and suitable for use in vaccinating an individual against neisserial infection, comprising an antigenic component having the properties:-
 - (a) it is of molecular weight at least 40kDa and up to 90kDa;
 - (b) it is obtainable from a commensal *Neisseria*; and
 - (c) antibodies to the component obtained from the commensal *Neisseria* cross-react with *N. meningitidis*.
13. A composition for eliciting an immune response and suitable for use in vaccinating an individual against neisserial infection, comprising an antigenic component having the properties:-
 - (a) it is of molecular weight at least 70kDa;
 - (b) it is obtainable from a commensal *Neisseria*; and
 - (c) antibodies to the component obtained from the commensal *Neisseria* cross-react with *N. meningitidis*.
14. A composition according to any of Claims 11 to 13 further comprising one or more of a transferrin binding protein, a Cu,Zn-SOD, a porin and NspA.
15. A composition for vaccination against neisserial infection comprising a

- 25 -

commensal *Neisseria* and a pharmaceutically acceptable carrier, wherein the commensal *Neisseria* expresses a gene from a pathogenic *Neisseria*.

16. A composition according to Claim 15 wherein the commensal *Neisseria* expresses a gene which encodes a protein from *N. meningitidis* selected from the group consisting of transferrin binding protein; a Cu,Zn-SOD; an NspA; a porin; and an outer membrane protein.
17. A pharmaceutical composition comprising a composition according to any of Claims 1 to 14 plus a pharmaceutically acceptable carrier.
18. A method of vaccination against microbial infection, comprising administering an effective amount of a composition according to any of Claims 1 to 17.
19. A method of vaccination against neisserial infection, comprising administering an effective amount of a composition according to any of Claims 1 to 17.
20. A commensal *Neisseria*, which expresses a gene from a pathogenic *Neisseria*.
21. A commensal *Neisseria* according to Claim 20, which expresses a *N.meningitidis* gene which codes for a protein selected from the group consisting of: a transferrin binding protein, a porin, NspA, an outer membrane protein, and a Cu,Zn-SOD.
22. A method of extracting a protein for incorporation in a composition suitable for vaccinating against meningococcal disease, comprising:-
 - (i) suspending commensal *Neisseria* cells in the presence of detergent;
 - and

- 26 -

- (ii) incubating the suspension so as to extract a protein fraction from the cells.
23. A method according to Claim 22, wherein the protein fraction is of molecular weight 50kDa or lower.
24. A method according to Claim 22, wherein the protein fraction is of molecular weight at least 40kDa and up to 90kDa.
25. A method according to Claim 22, wherein the protein fraction is of molecular weight at least 80kDa.
26. A method according to any of Claims 22 to 25 further comprising mixing the protein fraction with one or more of a transferrin binding protein, a Cu,Zn-SOD, a porin, an NspA and a meningococcal protein.
27. A pharmaceutical composition comprising an antibody that binds to a commensal *Neisseria* or an immunogenic component or extract thereof and a pharmaceutically acceptable carrier.
28. A composition for vaccinating against meningococcal disease substantially as hereinbefore described.
29. A composition comprising a commensal *Neisseria*, or an immunogenic component, extract or derivative thereof, wherein said *Neisseria* comprises a heterologous gene product.
30. A composition according to Claim 29 wherein the heterologous gene product is a product of a gene that is expressed in said commensal *Neisseria*.
31. A composition according to Claim 29 wherein the heterologous gene

- 27 -

product is physically combined with said commensal *Neisseria*.

32. A method of preparing a composition comprising:

- a) inserting a gene coding for a heterologous gene product into an expression vector;
- b) transforming said expression vector into a commensal *Neisseria* so that said heterologous gene product is expressed in said *Neisseria*; and
- c) combining the *Neisseria* of (b) with a pharmaceutically acceptable carrier.

33. A method of preparing a composition comprising the steps of:

- a) inserting a gene coding for a heterologous gene product into an expression vector;
- b) transforming said expression vector into a commensal *Neisseria* so that said heterologous gene product is expressed in said *Neisseria*;
- c) obtaining an immunogenic component or extract from the *Neisseria* of (b); and
- d) combining the immunogenic component or extract of (c) with a pharmaceutically acceptable carrier.

34. A method of preparing a composition comprising the steps of:

- a) obtaining an immunogenic component or extract of a



- 28 -

commensal *Neisseria*; and

b) combining the immunogenic component or extract of (a) with a heterologous gene product and a pharmaceutically acceptable carrier.

35. A method according to any of claims 29-34, wherein said commensal *Neisseria* is selected from the group consisting of *N. lactamica*; *N. cinerea*; *N. elongata*; *N. flavescens*; *N. polysaccharea*; *N. sicca*; and *N. subflava*.
36. Use of a commensal *Neisseria* in the manufacture of a medicament for treatment of neisserial infection.
37. Use of a commensal *Neisseria*, or an immunogenic component, extract or derivative thereof, wherein said *Neisseria* comprises a heterologous gene product, in the manufacture of a medicament for the treatment of infection in an animal.
38. Use of a commensal *Neisseria*, or an immunogenic component, extract or derivative thereof, wherein said *Neisseria* comprises a heterologous gene product, in the manufacture of a medicament for immunostimulation in an animal.

1/5

FIG. 1Challenge dose 10^8 CFU**FIG. 6**

2/5






FIG. 2A



3/5

FIG. 2B

4/5

FIG. 3





FIG. 4



5/5





FIG. 5



(19) World Intellectual Property Organization
International Bureau



(43) International Publication Date
31 August 2000 (31.08.2000)

PCT

(10) International Publication Number
WO 00/50074 A3

(51) International Patent Classification⁷: **A61K 39/095**,
C12N 1/21, C07K 14/22, A61K 39/40, C12N 15/31, A61P
31/04 // (C12N 1/21, C12R 1:36)

(21) International Application Number: PCT/GB00/00624

(22) International Filing Date: 22 February 2000 (22.02.2000)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
9904028.9 22 February 1999 (22.02.1999) GB
9922561.7 23 September 1999 (23.09.1999) GB

(71) Applicants (for all designated States except US): **MICROBIOLOGICAL RESEARCH AUTHORITY** [GB/GB]; CAMR, Porton Down, Salisbury, Wiltshire SP4 0JG (GB). **IMPERIAL COLLEGE SCHOOL OF SCIENCE, TECHNOLOGY AND MEDICINE** [GB/GB]; Sherfield Building, Exhibition Road, London SW7 2AZ (GB). **PUBLIC HEALTH LABORATORY SERVICE BOARD** [GB/GB]; 61 Colindale Avenue, London NW9 5DF (GB).

(72) Inventors; and

(75) Inventors/Applicants (for US only): **ROBINSON, Andrew** [GB/GB]; Microbiological Research Authority, CAMR, Porton Down, Salisbury, Wiltshire SP4 0JG (GB). **GORRINGE, Andrew, Richard** [GB/GB]; Microbiological Research Authority, CAMR, Porton Down, Salisbury, Wiltshire SP4 0JG (GB). **HUDSON, Michael, John** [GB/GB]; Microbiological Research Authority, CAMR, Porton Down, Salisbury, Wiltshire SP4 0JG (GB). **BRACEGIRDLE, Philippa** [GB/GB]; Microbiological Research Authority, CAMR, Porton Down,

Salisbury, Wiltshire SP4 0JG (GB). **KROLL, John, Simon** [GB/GB]; Imperial College School of Medicine, St. Mary's Hospital, Norfolk Place, London W2 1PG (GB). **CARTWRIGHT, Keith** [GB/GB]; Public Health Laboratory Service, Headquarters Office, 61 Colindale Avenue, London NW9 5DF (GB).

(74) Agents: **SCHLICH, George, William et al.**; Mathys & Squire, 100 Gray's Inn Road, London WC1X 8AL (GB).

(81) Designated States (*national*): AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW.

(84) Designated States (*regional*): ARIPO patent (GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).

Published:

- With international search report.
- Before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments.

(88) Date of publication of the international search report:
28 December 2000

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(54) Title: NEISSERIAL VACCINE COMPOSITIONS AND METHODS

(57) Abstract: Methods and compositions for the treatment of microbial infection, and in particular meningococcal disease, comprise a commensal *Neisseria* or an extract of a commensal *Neisseria*. Further methods and compositions comprise commensal *Neisseria* which express genes from virulent strains of *Neisseria* and/or heterologous gene products from non-neisserial sources. Such compositions are used in vaccine preparations for the treatment of microbial infection.

WO 00/50074 A3

INTERNATIONAL SEARCH REPORT

Inter. nal Application No

PCT/GB 00/00624

A. CLASSIFICATION OF SUBJECT MATTER

IPC 7 A61K39/095 C12N1/21 C07K14/22 A61K39/40 C12N15/31
A61P31/04 //(C12N1/21,C12R1:36)

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 7 A61K C07K C12N

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

EPO-Internal, WPI Data, PAJ, MEDLINE, BIOSIS

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	CANN K J ET AL: "DETECTION OF ANTIBODIES TO COMMON ANTIGENS OF PATHOGENIC AND COMMENSAL NEISSERIA SPECIES" JOURNAL OF MEDICAL MICROBIOLOGY, vol. 30, no. 1, 1989, pages 23-32, XP000946799 ISSN: 0022-2615 abstract page 23, left-hand column, line 23 -right-hand column, line 3,20-25 page 24, left-hand column, paragraph 2 page 30, right-hand column, paragraphs 2,3	1-10, 17-25, 27,28,36
A	<p style="text-align: center;">—</p> <p style="text-align: center;">-/-</p>	11-16, 26, 29-35, 37,38



Further documents are listed in the continuation of box C.



Patent family members are listed in annex.

* Special categories of cited documents:

- "A" document defining the general state of the art which is not considered to be of particular relevance
- "E" earlier document but published on or after the international filing date
- "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- "O" document referring to an oral disclosure, use, exhibition or other means
- "P" document published prior to the international filing date but later than the priority date claimed

- "T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
- "X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
- "Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.
- "&" document member of the same patent family

Date of the actual completion of the international search

4 October 2000

Date of mailing of the international search report

17/10/2000

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,
Fax: (+31-70) 340-3016

Authorized officer

Covone, M

INTERNATIONAL SEARCH REPORT

Inter. Appl. Application No.

PCT/GB 00/00624

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	<p>GOMEZ J A ET AL: "Antigenicity, cross-reactivity and surface exposure of the Neisseria meningitidis 37 kDa protein (Fbp)."</p> <p>VACCINE, vol. 14, no. 14, 1996, pages 1340-1346, XP004070969 ISSN: 0264-410X abstract page 1340, right-hand column, paragraph 2 page 1343, right-hand column, paragraph 2 page 1345, right-hand column, paragraph 5 table 1 figure 1</p>	<p>1-7, 10, 11, 17-23, 27, 28, 35</p>
X	<p>DATABASE BIOSIS 'Online! BIOSCIENCES INFORMATION SERVICE, PHILADELPHIA, PA, US; 1988 AOUN L ET AL: "HUMAN ANTIBODY RESPONSE TO THE 70-KD COMMON NEISSERIAL ANTIGEN IN PATIENTS AND CARRIERS OF MENINGOCOCCI OR NON-PATHOGENIC NEISSERIA" Database accession no. PREV198886026860 XP002149186 abstract & ANNALES DE L'INSTITUT PASTEUR MICROBIOLOGY, vol. 139, no. 2, 1988, pages 203-212, ISSN: 0769-2609</p>	<p>1, 5, 9, 17-20, 27, 28, 36</p>
X	<p>WO 96 29412 A (IAF BIO VAC INC ; BRODEUR BERNARD R (CA); MARTIN DENIS (CA); HAMEL) 26 September 1996 (1996-09-26) page 5, line 24 -page 6, line 12 page 13, line 31 -page 14, line 14</p>	<p>1, 5, 7, 17-20, 27, 28, 36</p>
P, X	<p>TRONCOSO G ET AL: "Antigenic cross-reactivity between outer membrane proteins of Neisseria meningitidis and commensal Neisseria species." FEMS IMMUNOLOGY AND MEDICAL MICROBIOLOGY, vol. 27, no. 2, February 2000 (2000-02), pages 103-109, XP000946807 ISSN: 0928-8244 page 104, left-hand column, paragraph 2 page 108, left-hand column, paragraphs 3, 4</p>	<p>1-10, 17-25, 27, 28, 36</p>

INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/GB 00/00624

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
WO 9629412 A	26-09-1996	AU 716225 B	24-02-2000
		AU 4934396 A	08-10-1996
		BR 9607651 A	17-11-1998
		CA 2215161 A	26-09-1996
		CZ 9702914 A	14-01-1998
		EP 0815234 A	07-01-1998
		HU 9702387 A	28-05-1998
		JP 11500624 T	19-01-1999
		NO 974264 A	13-11-1997
		PL 322363 A	19-01-1998
		SI 9620035 A	31-12-1998
		SK 125597 A	03-06-1998